Evelo's Rise and Fall: A Tragic Journey in Microbiome-based Therapies

Evelo, a pioneering company in the field of microbiome-based therapies, emerged as a global leader in researching immunotherapies for cancer, autoimmune, and inflammatory diseases. In 2016, Flagship facilitated the merger of Evelo and Epiva, with Evelo retaining its name. The merged company combined the groundbreaking research and candidate products of both teams, boasting over 50 patents and protected intellectual property rights. Backed by significant financing from Flagship, totaling approximately $40 million, Evelo attracted renowned investors such as Google Ventures, Celgene, and Mayo Clinic.

Early Success and High Expectations:
Within just four years of its establishment, Evelo successfully raised over $150 million in funding. In May 2018, Evelo completed its initial public offering (IPO), raising $85 million. The stock price of Evelo, as a flagship concept stock under Flagship, soared to $398 per share in 2021, fueled by the endorsement of star investment firms and the innovative concept of microbiome therapeutics.

Challenges in Drug Development:
Evelo's ambitious approach involved using single strains of bacteria encapsulated in capsules that, when ingested by patients, would reach the small intestine and lymphoid tissues associated with the gut. Dendritic cells would detect these changes in the gut and trigger immune responses specific to the sensed microbiota. Evelo developed an integrated platform to identify these unique strains and embarked on the development of ten pipelines, primarily focused on cancer and inflammatory diseases.

Series of Setbacks:
Despite the large pipeline, only EDP1867, EDP1815, and EDP2939, targeting inflammatory diseases, showed promising progress. However, Evelo faced setbacks when clinical trials failed to demonstrate significant efficacy. In late 2019, Evelo released phase 1b interim clinical data for EDP1815, indicating good tolerability but no overall difference in effectiveness compared to a placebo for patients with mild to moderate psoriasis.

EDP1815's Failure and Diminishing Hopes:
In February of this year, Evelo presented data showing that 41% of EDP1815-treated patients in Cohort 1, 38% in Cohort 2, and 32% in Cohort 3 achieved an EASI-50 response or higher at week 16. However, the placebo group had a higher response rate of 56%, varying significantly by geographical region. These disappointing results persisted in updated data released in April, ultimately leading to the complete failure of EDP1815.

The Last Hope and Ultimate Demise:
Evelo pinned its last hope on EDP2939, but the phase II clinical trial for treating psoriasis in October 2022 also ended in failure. These repeated clinical trial setbacks eroded investor confidence, causing Evelo's stock price to plummet to just $0.6 per share. Despite various attempts to reverse its fortunes, including pipeline reductions, significant layoffs, management changes, and seeking sales or mergers, Evelo's efforts proved futile.

Evelo's journey epitomizes the challenges faced by many biotech companies in the pursuit of innovative therapies. Despite its novel concepts, strong financial backing, and renowned investors, Evelo's repeated clinical failures and financial constraints led to its downfall. With accumulated losses of $588 million and dwindling cash reserves, the company chose to close its operations, repay debts to creditors, and potentially return a portion of remaining cash to shareholders. Evelo's rise and subsequent fall serve as a cautionary tale in the ever-evolving landscape of biotech ventures.